Switch Therapeutics
Biotechnology, 2199 S McDowell BLVD Ext, San Francisco, California, 94954, United States, 11-50 Employees
Phone Number: +16*********
Who is SWITCH THERAPEUTICS
Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) scienc...
Read More
-
Headquarters: 2199 S McDowell BLVD Ext, San Francisco, California, 94954, United States
-
Date Founded: 2020
-
Employees: 11-50
-
Revenue: $250 Million to $500 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from SWITCH THERAPEUTICS
Switch Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Switch Therapeutics
Answer: Switch Therapeutics's headquarters are located at 2199 S McDowell BLVD Ext, San Francisco, California, 94954, United States
Answer: Switch Therapeutics's phone number is +16*********
Answer: Switch Therapeutics's official website is https://switchthera.com
Answer: Switch Therapeutics's revenue is $250 Million to $500 Million
Answer: Switch Therapeutics's SIC: 2834
Answer: Switch Therapeutics's NAICS: 325412
Answer: Switch Therapeutics has 11-50 employees
Answer: Switch Therapeutics is in Biotechnology
Answer: Switch Therapeutics contact info: Phone number: +16********* Website: https://switchthera.com
Answer: Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases affecting the central nervous system and systemic indications with significant unmet needs. Switchs novel gene knockdown approach is based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard and City of Hope. Based on the scientific discovery of Switchs co-founders, the company has developed a novel proprietary platform known as CASi (Conditionally Activated siRNAs) that combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. To date, Switch has raised $52M in funding through Series A, and the companys South San Francisco based team has continued to grow as its research has advanced.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month